HIV acquires functional adhesion receptors from host cells.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

HIV acquires functional adhesion receptors from host cells.

AIDS Res Hum Retroviruses. 1995 Sep;11(9):1007-13. Unique Identifier : AIDSLINE MED/96089207
Guo MM; Hildreth JE; Department of Pharmacology and Molecular Sciences, Johns Hopkins; University School of Medicine, Baltimore, Maryland 21205, USA.

Abstract: CD4 is known to serve as the principal cellular receptor for HIV. However, several observations suggest that other molecules may be involved in infection of cells by HIV. Cell adhesion molecules and their ligands expressed on HIV-susceptible cells have been implicated in the biology of HIV in a number of studies. We have recently reported that HIV and SIV acquire cell adhesion molecules from host cells. We now report that a specific cell adhesion molecule, CD44, that is acquired by HIV retains its biological activity when expressed on the virus. We tested CEMx174 cells, which are CD4-positive and HIV-susceptible for phorbol ester-inducible binding to hyaluronic acid through CD44. Phorbol ester-stimulated but not unstimulated CEMx174 cells bound hyaluronic acid. Likewise, HIV from stimulated cells but not from unstimulated cells bound hyaluronic acid through acquired CD44 molecules. This is the first demonstration that adhesion molecules acquired by HIV are functional and the results imply that HIV may have the capacity to bind to any cell or substrate that its host cell binds to. The demonstration of functional adhesion receptors on HIV has important implications with respect to the tropism, infectivity, and dissemination of HIV.

Keywords: Antigens, CD44/*PHYSIOLOGY Cell Adhesion/DRUG EFFECTS/PHYSIOLOGY Cell Adhesion Molecules/PHYSIOLOGY Cell Line CD4-Positive T-Lymphocytes/IMMUNOLOGY/METABOLISM/VIROLOGY Human Hyaluronic Acid/METABOLISM HIV/*PHYSIOLOGY/PATHOGENICITY Models, Biological Receptors, HIV/*PHYSIOLOGY Support, U.S. Gov't, P.H.S. Tetradecanoylphorbol Acetate/PHARMACOLOGY JOURNAL ARTICLE
960530
M9651099

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .